The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $57,977,681 in first-year total cost, median $2,658,904.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IFCN-N (55)]19
- Special Emphasis Panel[ZRG1 IFCN-B (07)]3
- Special Emphasis Panel[ZRG1 IFCN-E (07)]2
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY3
- UNIVERSITY OF MARYLAND BALTIMORE3
- UNIVERSITY OF TX MD ANDERSON CAN CTR3
- UNIV OF NORTH CAROLINA CHAPEL HILL2
- UNIVERSITY OF ARIZONA2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Validation of Novel Target for OA Treatment1R01AR077890-01 | ROYSTON, THOMAS J | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $4,154,344 | ZRG1 |
| 2020 | Targeting Endosomal Receptors for Treatment of Chronic Pain1R01DE029951-01 | BUNNETT, NIGEL WSCHMIDT, BRIAN L | NEW YORK UNIVERSITY, NY | $3,385,528 | ZRG1 |
| 2020 | Novel target identification for treatment of chronic overlapping pain using multimodal brain imaging1R01DE029074-01A1 | MELEMEDJIAN, OHANNES KEVORKTRAUB, RICHARD J | UNIVERSITY OF MARYLAND BALTIMORE, MD | $2,980,325 | ZRG1 |
| 2020 | Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment1R01NS116704-01 | SHEPHERD, ANDREW JOHN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,908,421 | ZRG1 |
| 2020 | Targeting GPCRs in amygdalar and cortical neural ensembles to treat pain aversion1R01NS118504-01 | SCHERRER, GREGORY | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $2,802,899 | ZRG1 |
| 2020 | FKBP51 antagonism to prevent chronic pain: optimizing efficacy & evaluating safety and mechanisms1R01NS118563-01A1 | LINNSTAEDT, SARAHMCLEAN, SAMUEL A. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $2,589,652 | ZRG1 |
| 2020 | Subchondral Bone Cavities in Osteoarthritis Pain1RF1AG068997-01 | CAO, XUGUAN, YUN | JOHNS HOPKINS UNIVERSITY, MD | $2,521,652 | ZRG1 |
| 2020 | B Lymphocyte-Mediated Autoimmunity in Pain After Trauma1R01NS117340-01 | CLARK, DAVID J. | PALO ALTO VETERANS INSTIT FOR RESEARCH, CA | $2,454,998 | ZRG1 |
| 2020 | Identification of novel targets for the treatment of chemotherapy-induced painful peripheral neuropathy1R01CA249939-01 | MELEMEDJIAN, OHANNES KEVORK | UNIVERSITY OF MARYLAND BALTIMORE, MD | $1,545,000 | ZRG1 |
| 2020 | Validating ASCT2 for the Treatment of Chronic Postsurgical Pain1R01NS116759-01 | MELEMEDJIAN, OHANNES KEVORK | UNIVERSITY OF MARYLAND BALTIMORE, MD | $1,545,000 | ZRG1 |
| 2020 | Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain1R01NS120663-01A1 | KHANNA, RAJESH | UNIVERSITY OF ARIZONA, AZ | $395,680 | ZRG1 |
| 2020 | Validation of Spinal Neurotensin Receptor 2 as an Analgesic Target1R01NS116694-01 | PATWARDHAN, AMOL M | UNIVERSITY OF ARIZONA, AZ | $164,062 | ZRG1 |
| 2019 | Discovery and validation of a new long noncoding RNA as a novel target for neuropathic pain1RF1NS113881-01 | DAVIDSON, STEVETAO, YUAN-XIANG | RBHS-NEW JERSEY MEDICAL SCHOOL, NJ | $3,464,207 | ZRG1 |
| 2019 | LIGHT and Lymphotoxin targeting for the treatment of chronic orofacial pain conditions1R01DE029187-01 | AKOPIAN, ARMEN NRUPAREL, SHIVANI BTUMANOV, ALEXEI V | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $3,227,250 | ZRG1 |
| 2019 | Nrf2 Activation for Addiction-Free Treatment of Neuropathic Pain1RF1NS113840-01 | GRACE, PETER M | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $3,224,916 | ZRG1 |
| 2019 | Target validation of a novel CGRP receptor in migraine1RF1NS113839-01 | HAY, DEBBIE LRUSSO, ANDREW F | UNIVERSITY OF IOWA, IA | $3,089,543 | ZRG1 |
| 2019 | Sympathetic-mediated sensory neuron cluster firing as a novel therapeutic target for neuropathic pain1RF1NS113883-01 | DONG, XINZHONGZHANG, JUN-MING | JOHNS HOPKINS UNIVERSITY, MD | $3,057,232 | ZRG1 |
| 2019 | Validation of blocking TSP4/Cava2d1 interaction as a new target for neuropathic pain1R01DE029202-01 | LUO, ZHIGANG DAVID | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $2,940,765 | ZRG1 |
| 2019 | Dnmt3a as an epigenetic target for chronic pain treatment1RF1NS113256-01 | PAN, ZHIZHONG Z. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,728,155 | ZRG1 |
| 2019 | Discovery and validation of a novel orphan GPCR as a target for therapeutic intervention in neuropathic pain1R01NS113257-01 | SALVEMINI, DANIELAYOSTEN, GINA L.C. | SAINT LOUIS UNIVERSITY, MO | $2,156,764 | ZRG1 |
| 2019 | Targeting sensory ganglia and glial signaling for the treatment of acute and chronic pain1R01NS113243-01 | BERTA, TEMUGIN | UNIVERSITY OF CINCINNATI, OH | $2,006,250 | ZRG1 |
| 2019 | Validation of peripheral CGRP signaling as a target for the treatment of pain in chronic pancreatitis1R01DK123138-01 | PASRICHA, PANKAJ J | JOHNS HOPKINS UNIVERSITY, MD | $1,927,979 | ZRG1 |
| 2019 | Disrupting Ion Channel Scaffolding to Treat Neuropathic Pain1RF1NS113991-01 | BHATTACHARJEE, ARINDAM | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $1,901,926 | ZRG1 |
| 2019 | Identification and Validation of a Novel Central Analgesia Circuit1R01DE029342-01 | MATHEW, JOSEPH PWANG, FAN | DUKE UNIVERSITY, NC | $805,133 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.